TL;DR
This study identifies two key genes, GDF15 and IGFBP7, as being significantly associated with hyperemesis gravidarum (HG), a severe form of nausea and vomiting during pregnancy. By conducting a large-scale genome-wide association study (GWAS) and replicating findings in an independent cohort, the research provides crucial insights into the genetic underpinnings of this debilitating condition.
What Problem Does This Paper Address?
Hyperemesis gravidarum (HG) is a severe pregnancy complication affecting 0.3-2% of pregnancies, leading to significant maternal and fetal morbidity. Despite its prevalence and severity, the underlying causes of HG remain largely unknown. While familial aggregation and twin studies strongly suggest a genetic component, specific genetic risk factors have not been identified. This lack of understanding hinders the development of effective treatments and diagnostic tools. This paper aims to bridge this knowledge gap by employing a genetic approach to pinpoint genes associated with HG.
Methods
The researchers utilized a genome-wide association study (GWAS) approach, a standard technique for identifying genetic variants associated with complex traits. They conducted two separate GWAS scans:
- SCAN1: This scan analyzed a binary phenotype, comparing women with HG (defined by requiring intravenous fluid therapy) against controls who reported no nausea and vomiting of pregnancy (NVP).
- SCAN2: This scan analyzed an ordinal phenotype, assessing the severity of NVP on a scale from none to very severe.
For both scans, they used data from 23andMe customers of European ancestry who consented to participate in research. After identifying significant genetic loci (regions on chromosomes) in these initial scans, the findings were replicated in an independent cohort of women with clinically defined HG. This replication step is crucial for validating the initial findings and ensuring they are not due to chance or population-specific effects.
Datasets
The primary datasets used in this study were derived from 23andMe's customer base.
- SCAN1: Included 1306 HG cases and 15,756 controls.
- SCAN2: Included 53,731 participants with varying degrees of NVP severity.
The replication cohort consisted of:
- HG-IV: 789 women with HG requiring IV fluid treatment and 606 controls with normal NVP.
- HG-TPN: 110 women with HG requiring total parenteral nutrition (TPN) and 143 controls with no NVP.
These datasets were specifically collected and curated for this research, with detailed phenotype definitions provided in the methods section.
Key Insights and Ideas
- Two key genetic loci identified: The study pinpointed two specific chromosomal regions, chr19p13.11 and chr4q12, that were consistently associated with HG across both GWAS scans and replicated in an independent cohort. This provides strong evidence for their involvement.
- GDF15 and IGFBP7 implicated: The genes located within these significant loci are GDF15 and IGFBP7. Both genes are known to play roles in crucial biological processes relevant to pregnancy and maternal health.
- Functional relevance of GDF15: GDF15 is involved in placentation, appetite regulation, and cachexia (a wasting syndrome). Its role in suppressing inflammatory cytokines to facilitate placentation and its known impact on appetite and body weight regulation via the hypothalamus and area postrema (the brain's vomiting center) make it a compelling candidate for explaining HG symptoms. The study also notes that abnormal GDF15 levels are linked to cancer anorexia and cachexia, which share symptoms with HG.
- Functional relevance of IGFBP7: IGFBP7 is also implicated in implantation and decidualization of the uterus, and is highly expressed in the developing placenta. Its similar roles to GDF15 in placentation and cachexia strengthen the argument for its involvement.
- Potential therapeutic implications: The known roles of GDF15 and IGFBP7 in appetite regulation and cachexia suggest potential therapeutic avenues. If GDF15 is confirmed as a causal factor, drugs targeting this protein could potentially be developed for HG treatment, similar to strategies being explored for cancer cachexia.
Key Results
- Genome-wide significant associations: Two loci, chr19p13.11 and chr4q12, reached genome-wide significance (p < 5 × 10⁻⁸) in both GWAS scans.
- Replication of findings: These two loci were successfully replicated in an independent cohort (HG-IV), with rs16982345 (a proxy for the chr19p13.11 signal) showing a significant association (p = 2.8 × 10⁻⁷, OR = 1.63). The chr4q12 signal was also replicated (p = 3.5 × 10⁻⁴, OR = 1.35).
- Meta-analysis: Combined analysis of SCAN1 and replication cohorts further strengthened the association for rs16982345 (meta-OR = 1.50, p = 2.12 × 10⁻¹⁹) and rs4865234 (meta-OR = 1.33, p = 9.29 × 10⁻¹²).
- GDF15 expression link: Variants in high linkage disequilibrium (LD) with the associated SNPs at chr19p13.11 were found to be associated with altered GDF15 expression.
Limitations and Future Work
- Causality not proven: The study acknowledges that while strong associations were found, proving the causal roles of GDF15 and IGFBP7 in HG requires further investigation.
- Distance to IGFBP7: A notable limitation is the considerable distance between the chr4q12 association signal and the closest gene, IGFBP7, and the lack of direct eQTL (expression quantitative trait loci) data linking the variant to IGFBP7 expression in relevant tissues.
- Replication of secondary signals: While conditional analysis identified additional association signals at chr19p13.11, these were not replicated, highlighting the need for further validation.
- Ethnic diversity: The current findings are primarily based on individuals of European ancestry. Replication in larger, diverse ethnic cohorts is necessary for generalizability.
- Future Directions:
- Functional follow-up: Investigating the precise biological mechanisms by which GDF15 and IGFBP7 contribute to HG.
- Serum concentration studies: Measuring GDF15 and IGFBP7 levels in pregnant women with and without HG to assess their potential as biomarkers for prediction and diagnosis.
- Drug development: Exploring therapeutic strategies targeting GDF15 or IGFBP7.
- Discovery of additional loci: Further GWAS studies, particularly with larger sample sizes and diverse populations, are encouraged to identify more genetic risk factors for HG and NVP.
Summary updated